{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-020417","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2026-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.600425+00:00","generated_at":"2026-05-15T00:57:31.163715+00:00","sec_items":["1.01","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Evofem signs exclusive 5-year distributorship for SOLOSEC in sub-Saharan Africa with Clovis Davis","bullets":["Exclusive 5-year distribution agreement with Clovis Davis for SOLOSEC in sub-Saharan Africa, effective April 24, 2026.","SOLOSEC is an FDA-approved single-dose oral treatment for bacterial vaginosis and trichomoniasis.","Clovis Davis to lead distribution, promotion, and sales; regulatory filings based on US FDA dossier.","BV affects ~25% of women in sub-Saharan Africa; 10.9M women eligible in Ethiopia alone.","No upfront payments or financial terms disclosed; partnership aims to expand global reach."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-020417","json":"https://secwatch.observer/filing/0001493152-26-020417.json","markdown":"https://secwatch.observer/filing/0001493152-26-020417.md","text":"https://secwatch.observer/filing/0001493152-26-020417.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T00:57:31.163715+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9733ef1e5bfded64f48a31cad5709a3d17ddf7d4","claim":"Evofem Biosciences, Inc. entered into Distributorship Agreement with Clovis Davis Pharmaceuticals, LLC. (effective 2026-04-24).","evidence_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-251791","ticker":"KRMN","company_name":"Karman Holdings Inc.","filed_at":"2026-06-01T21:28:29+00:00","headline":"Selling stockholders price upsized secondary offering of 14M shares at $61/share for ~$854M gross proceeds","event_type":"other_material","sec_items":["1.01","7.01","8.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251791","json":"https://secwatch.observer/filing/0001193125-26-251791.json","markdown":"https://secwatch.observer/filing/0001193125-26-251791.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/d117104d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 28, 2026, Karman Holdings Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with the persons named in Schedule II thereto (the “Selling Stockholders”) and Citigroup Global Markets Inc. and Evercore Group L.L.C., as the underwriters (the “Underwriters”), pursuant to which the Selling Stockholders agreed to sell 14,000,000 shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) at a public offering price of $61.00 per share (the “Offering Price”), less underwriting discounts and commissions (the “Offering”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2040127/000119312526251791/0001193125-26-251791-index.htm"}},{"accession":"0001213900-26-063565","ticker":"AIB","company_name":"BlockchAIn Digital Infrastructure, Inc.","filed_at":"2026-06-01T20:57:13+00:00","headline":"Blockchain Digital signs 15-yr, 65 MW electric agreement at CLT-01; 25 MW LOIs in pipeline","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-063565","json":"https://secwatch.observer/filing/0001213900-26-063565.json","markdown":"https://secwatch.observer/filing/0001213900-26-063565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/ea0292328-8k_blockchain.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 27, 2026, One Blockchain, LLC, a subsidiary of BlockchAIn Digital Infrastructure, Inc. (the “Company”) entered into a 15-year Electric Service Agreement (“Electric Service Agreement”) with a local utility provider (the “Utility Company”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2070542/000121390026063565/0001213900-26-063565-index.htm"}},{"accession":"0001683168-26-004424","ticker":"LTRX","company_name":"LANTRONIX INC","filed_at":"2026-06-01T20:15:28+00:00","headline":"Lantronix prices $30M common stock offering at $7.20/share; net proceeds ~$32.3M","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001683168-26-004424","json":"https://secwatch.observer/filing/0001683168-26-004424.json","markdown":"https://secwatch.observer/filing/0001683168-26-004424.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/lantronix_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 29, 2026, Lantronix, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Needham & Company, LLC and Canaccord Genuity LLC, as underwriters (together, the “Underwriters”), pursuant to which the Company agreed to sell, and the Underwriters agreed to purchase, 4,166,667 shares (the “Firm Shares”) of the Company’s common stock","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1114925/000168316826004424/0001683168-26-004424-index.htm"}},{"accession":"0001493152-26-022133","ticker":"BNAI","company_name":"Brand Engagement Network Inc.","filed_at":"2026-05-11T23:59:59+00:00","headline":"BEN invests $1M in Accelevate, signs exclusive Mexico reseller and global deal","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-022133","json":"https://secwatch.observer/filing/0001493152-26-022133.json","markdown":"https://secwatch.observer/filing/0001493152-26-022133.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/form8-k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 7, 2026, following the successful completion of due diligence, entered into two definitive Reseller Agreements (the “Commercial Agreements”) with Accelevate.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1838163/000149315226022133/0001493152-26-022133-index.htm"}},{"accession":"0001193125-26-214698","ticker":"PBT","company_name":"PERMIAN BASIN ROYALTY TRUST","filed_at":"2026-05-08T23:59:59+00:00","headline":"Court approves trust indenture amendments eliminating 75% supermajority requirement","event_type":"other_material","sec_items":["1.01","3.03","5.03","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-214698","json":"https://secwatch.observer/filing/0001193125-26-214698.json","markdown":"https://secwatch.observer/filing/0001193125-26-214698.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/0001193125-26-214698-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/2026-05_pbt_rslt_of_hear.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"Argent Trust Company, the trustee of the Trust, entered into Amendment No. 2 to the Amended and Restated Trust Indenture of Permian Basin Royalty Trust dated May 8, 2026 (the “Amendment”) implementing the modifications approved by the Court.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/319654/000119312526214698/0001193125-26-214698-index.htm"}},{"accession":"0001213900-26-053475","ticker":null,"company_name":"MEDICAL EXERCISE INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Medical Exercise signs first franchise agreement for Canadian OnCore Longevity Center","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053475","json":"https://secwatch.observer/filing/0001213900-26-053475.json","markdown":"https://secwatch.observer/filing/0001213900-26-053475.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/ea0289708-8k_medical.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026053475/0001213900-26-053475-index.htm"}},{"accession":"0001213900-26-053524","ticker":"HOVR","company_name":"New Horizon Aircraft Ltd.","filed_at":"2026-05-08T23:59:59+00:00","headline":"New Horizon Aircraft raises ~$20M in registered direct offering of 9.25M shares at $2.15","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-053524","json":"https://secwatch.observer/filing/0001213900-26-053524.json","markdown":"https://secwatch.observer/filing/0001213900-26-053524.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/ea0289712-8k_newhorizon.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 6, 2026, New Horizon Aircraft Ltd. (the “Company”) entered into Securities Purchase Agreements (the “Purchase Agreements”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered direct offering (the “Offering”) an aggregate of 9,254,889 our Class A ordinary shares, without par value (the “Shares\", and each Class A ordinary share with no par value in the authorized share structure of the Company, a “Common Share”). The offering price per Share is $2.15, for aggregate gross proceeds to the Company from the Offering of approximately $19.9 million","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1930021/000121390026053524/0001213900-26-053524-index.htm"}},{"accession":"0001213900-26-054034","ticker":null,"company_name":"MEDICAL EXERCISE INC.","filed_at":"2026-05-08T23:59:59+00:00","headline":"Medical Exercise signs first OnCore franchise in Regina, Canada; exits back pain market","event_type":"other_material","sec_items":["1.01","7.01","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 7.01, 9.01","same event type: other_material","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054034","json":"https://secwatch.observer/filing/0001213900-26-054034.json","markdown":"https://secwatch.observer/filing/0001213900-26-054034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/0001213900-26-054034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/ea0289883-8ka1_medical.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 24, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), entered into an exclusive distributorship agreement with Clovis Davis Pharmaceuticals, LLC., a Delaware Limited Liability Company (“Clovis Davis”) to commercialize SOLOSEC® (secnidazole) 2 g oral granules product in Sub-Saharan Africa (the “Territory”) for a period of five years commencing on April 24, 2026.","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226020417/0001493152-26-020417-index.htm","comparable_excerpt":"On May 6, 2026, Medical Exercise Inc. (the “Company”) entered into a Franchise Agreement (the “Agreement”) with Degco Fitness Ventures Ltd., a corporation based in Regina, Saskatchewan, Canada.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2001249/000121390026054034/0001213900-26-054034-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}